All posts by Sean Mason

CSE Issuer Stories, Magazine

BioHarvest Sciences: Revolutionizing the Health Industry With Botanical Synthesis

Imagine a world where we harness the power of plants to improve human wellness without harming the environment. Israeli biotech innovator BioHarvest Sciences (CSE:BHSC) is turning this vision into reality through its Bio-Plant CELLicitation plant cell technology, which is paving the way for a new era of sustainable and highly effective botanical compositions.

BioHarvest’s patented technology sets the company apart from traditional agriculture by producing botanical compositions without the need to grow the entire plant. These compositions are rich in primary and secondary metabolites such as proteins, phenolics, terpenes, steroids and alkaloids, which are of significant value to the nutrition and health industries. The botanical compositions produced through BioHarvest’s platform technology are highly bioavailable, consistent, pure, patentable and environmentally sustainable.

One of the company’s notable successes is its flagship product VINIA, a botanical composition derived from red grape cells that contains high levels of polyphenols, particularly piceid resveratrol.

VINIA has undergone multiple clinical trials and has proven to be effective for various therapeutic applications, having gained recognition for its ability to increase arterial dilation, improving blood flow throughout the body and supporting heart health, physical energy, mental alertness and cellular protection.

“The current global market for nutraceuticals is approximately US$160 billion and it is growing rapidly,” BioHarvest Sciences Chief Executive Officer Ilan Sobel tells Canadian Securities Exchange Magazine. “VINIA is uniquely positioned in this market because of its clinically proven efficacy and its successful track record with consumers over the last three years.”

Sobel says BioHarvest aims to achieve market share of at least 5% in the US cardiovascular and energy health segments within the next 36 months.

CELLicitation involves growing cells from different parts of the plant in liquid solutions inside large disposable bioreactors, and the platform has already been validated across multiple plant-derived compositions. The process allows BioHarvest to produce cells that contain the plant’s primary and secondary metabolites, known as phytochemicals, in a controlled and efficient manner.

And the company is building undeniable momentum. In 2022, BioHarvest reported revenue of US$5.5 million, a 179% increase from the previous year.

For 2023, BioHarvest anticipates revenue of $17 million to $20 million, which works out to around 300% growth compared to 2022. It also expects to break even at a cash operating level in the fourth quarter.

BioHarvest’s customer base is largely subscription based, and customer satisfaction is high, with a current rating of 4.8 out of 5 from over 2,200 reviews. The company plans to further expand its sales channels, including partnerships with major retailers such as Walmart.com, Amazon, and direct-to-doctor sales through integrative medicine specialists.

“We have announced the addition of 25,000 [direct-to-consumer] new customers in the last 12 months, and our current growth is limited only by our production capacity, which we are increasing significantly,” Sobel adds.

To support the anticipated growth, Sobel says the company’s newly designed production facility has annual production capacity of 20 tons, which is enough to meet its global operations plan for the next two years. The company is currently in the process of scaling up production to reach the maximum capacity.

Plans also call for building a larger facility with a capacity of 100 tons per year. To aid this expansion, BioHarvest recently hired Dr. Ilana Belzer as its first Chief Operating Officer to oversee manufacturing, including the development of new technologies to improve yield and reduce production costs.

Furthermore, the BioHarvest Sciences CEO says the company is diversifying its product channels by developing new formulations that incorporate VINIA into coffee, tea and protein bars. These are set to be available in late 2023 and early 2024.

BioHarvest is also looking to grow through other channels, particularly sports partnerships due to the obvious benefits its products can provide to athletes.

“Our recent partnership with Yo Murphy of the House of Athlete is an example of a unique program, where we just saw four of his ‘Team VINIA’ NFL prospects selected in the 2023 NFL draft,” Sobel says. “The partnership is a significant milestone for BioHarvest and demonstrates the potential of its innovative technology to revolutionize the sports nutrition industry.”

More partnerships and programs are in development, which includes VINIA being added to the NFL pre-season training regimens of over 140 players.

The company holds 15 approved patents covering its unique process and compositions. Additionally, the team’s accumulated know-how from 15 years of research and development further strengthens its position as a leader in the field.

“BioHarvest’s technology is poised to make a big difference in the health and wellness industry by availing patentable botanical compositions for therapeutic purposes that can be in the form of nutraceuticals and pharmaceuticals,” Sobel explains.

He says BioHarvest aims to lead the botanical synthesis revolution by utilizing the power of plants to improve human wellness while at the same time prioritizing environmental sustainability, which is evident in the company’s plans to leverage its expertise in research and development, manufacturing and commercialization.

BioHarvest is already working on expanding its product line to include additional products, with olive and pomegranate cell banks at the advanced development stage. A robust clinical trial program is underway, as the company tests product impact against specific medical indications. These clinical studies are designed to not only potentially augment the functional claims for different products but also to further the potential for those products to ultimately be included in pharmaceuticals, as either approved drugs or adjuncts to approved drugs.

This story was featured in Canadian Securities Exchange Magazine.

Learn more about BioHarvest Sciences at https://bioharvest.com/

CSE Issuer Stories, Magazine

Western Uranium & Vanadium: Sights Set on Becoming a Global Leader in Low-Cost Production of Uranium and Vanadium

Nuclear energy is positioned as a key component in the worldwide push to reduce carbon emissions. Nuclear reactors, after all, generate power through heat released by fission, which is used to create steam that spins a turbine to generate electricity without the harmful emissions associated with fossil fuels.

Uranium demand to fuel the world’s nuclear reactors is expected to rise to 79,400 metric tonnes of elemental uranium (MTU) by 2030, up from 62,500 MTU in 2021, with that number anticipated to climb to 112,300 MTU in 2040, according to a report by the World Nuclear Association.

Colorado-based Western Uranium & Vanadium (CSE:WUC) is a mining company focused on low-cost, near-term production of uranium and vanadium in the western United States. The company has a large production-ready, permitted and developed high-grade uranium and vanadium resource, which includes the Sunday Mine Complex developed by Union Carbide for almost US$50 million in the 1970s.

Chief Executive Officer George Glasier has a record of uranium mining success, having founded Energy Fuels, which is currently the largest uranium and vanadium resource holder in the US. On a recent call with Canadian Securities Exchange Magazine, Glasier discussed Western Uranium & Vanadium’s goal of becoming a low-cost uranium and vanadium producer, as well as why now could be a good time for investors to consider companies in the space.

Tell us about why you were motivated to form Western Uranium & Vanadium.

The motivation was the expected increase in the price of uranium and vanadium. I’ve been in that industry for years, having previously formed Energy Fuels, and I was also involved with the original company called Energy Fuels Nuclear back in the late 1970s and early 1980s, which became the largest uranium producer in the US. 

When the industry was in bad shape and commodity prices were low, there was no reason to consider being in the uranium mining business. But as prices looked like they were going to rebound, we formed Western Uranium & Vanadium in 2014 to buy a key asset package from Energy Fuels.

So, my motivation was to take advantage of these incredible properties that we could acquire at a reasonable price for the expected uranium boom and get back into the uranium business with a profitable company.

Why might now be a good time for investors to consider uranium and vanadium stocks?

Well, because I don’t think we’ve reached the peak, and the CEO of Bannerman Energy just said we need an $80 per pound uranium price around the world to produce the supplies needed to keep reactors operating.

Let’s say we’re at a spot price of around $50 and maybe we’re at a term price of $60. But to incentivize additional production, we need an $80 uranium price. And at $80 there are a number of companies that stand to make quite a bit of money, including the explorers over the longer term. If an investor wants to get into a commodity, there’s probably not a better commodity right now than uranium with the expected price increase.

Our company is a dual producer of uranium and vanadium, which is very unusual, as most uranium companies don’t have vanadium. And vanadium, which had been used primarily as an alloy for steel, is now being used in vanadium redox flow batteries for stationary energy storage. This should provide a real boost to the demand for vanadium around the world and ultimately increase the value of vanadium.

I think that investing in a company that has both uranium and vanadium as commodities could be a double win, as both seem set to increase in value over the next five years.

Your company has stated that production will be restarting soon at the Sunday Mine Complex. What is required to begin operations there?

The process has begun. In fact, we just hired two new people this week, and we’re hiring the rest of the crew who will be on board after the first of the year. And we’ve already got all the equipment we need for the first stages of production.

The mine was in production as recently as 2022, but the mining contractor wanted to shut down for various reasons, mostly due to his health. So, we did that and began buying mining equipment, starting with his. We thus have very little to do to get started — just really hire some more employees. The mine is fully permitted, developed and ready to go, and we will be back at that mine in January with our production crews.

In May, you announced revenue from a uranium concentrate supply agreement. Are there any other near-term revenue opportunities for the company?

We own oil and gas royalties that generate revenue of up to $50,000 a month, and the operator just drilled additional wells to bring into production. It’s a revenue stream that we have, and it’s kind of unique for a uranium and vanadium company. And while the revenue it generates is not insignificant, it won’t be a value creator for our company.  

Do you plan on adding more oil and gas royalties? 

No, this just happens to be a uranium property we acquired with additional minerals. We’re not an oil and gas company, and we’re not a royalty company. But we had the assets, so we took advantage of that by leasing it to an oil company, and they drilled these wells in the oil and gas fields of northern Colorado.

We don’t intend to acquire more oil and gas royalties. We’re a uranium and vanadium producer, and we do that well. That being said, we could go on collecting these royalties for another 20 or 30 years. 

What do your shareholders have to look forward to in the next 12 months?

We recently came out with some big news that really sets the stage for everything else this year. After many months of assessing locations, we found the perfect site for building the processing plant that will handle ore from the Sunday Mine Complex and ore from our other projects, as well as feed from other conventional miners.

So, it’s great as a team to have acquired land parcels in Utah for the facility, and now we’ll be going all out to get it into mill production as fast as reasonably possible.

Permitting is our focus right now, and we are targeting 2026 for initial mill production. At start-up, the plan is to produce 2 million pounds of uranium per year and 5 million to 6 million pounds of vanadium.  A cobalt circuit will be designed and constructed if there is enough interest from nearby companies who have cobalt ore.

I’d also highlight that in addition to substantial production coming out of the Sunday Mine, we will be expanding extraction into each of the five mines comprising the broader Sunday Complex. It’s reasonable to anticipate two or three crews working at the complex by the end of 2023. We’ll be stockpiling ore there so that we’re ready to provide consistent feed to the processing facility.

Is there anything else that you want prospective investors to know about your company?

We believe this industry has a real future. We’re a small company, we’re well-staffed with good people and we’ve got great resources. If you look at our resource base, it may not all be NI-43-101 compliant, but we carry over 50 million pounds of historical resources based upon limited drilling. And our resource base with high-grade uranium and vanadium is probably going to be some of the lowest-cost production in North America, if not the world.

This story was featured in Canadian Securities Exchange Magazine.

Learn more about Western Uranium & Vanadium at western-uranium.com.

CSE Issuer Stories, Magazine

Marimed: More US Growth in the Works for This Consistently Profitable Cannabis Company

Consumer demand for legal cannabis continues to grow in the US despite stalled legalization efforts at the federal level. Analytics company New Frontier Data, for example, projects US cannabis sales will hit US$57 billion annually by 2030, with that number possibly reaching $72 billion if 18 additional states permit adult recreational use.

MariMed (CSE:MRMD) has developed into a premier seed-to-consumer multi-state operator with expertise in cultivation, production and dispensary operations. The company has a track record of sustainable revenue growth along with one of the strongest EBITDA margins in the industry, projecting $135 million to $140 million in revenue for 2022, as well as $35 million to $40 million in adjusted EBITDA.

The Canadian Securities Exchange Magazine recently spoke with MariMed President Jon Levine, who discussed the company’s growth prospects, how it plans to increase shareholder value and the ways in which US federal legalization efforts influence MariMed’s business.

What distinguishes MariMed from other US multi-state operators?

MariMed is a company that prides itself on its history and a leadership team with a strong track record of winning licences. We built this company over several years – first as advisors helping businesses win their applications and building out their facilities, and now as acquirers working to consolidate those businesses under the MariMed footprint.

Today, we have a lot of team members and facilities with deep industry knowledge, including several members of our executive leadership team. Our CEO Bob Fireman, COO Tim Shaw and I have been working together in this industry for more than a decade.

Why did you choose the states in which you operate, and do you have plans to expand to other states?

In the beginning, MariMed submitted applications in multiple states that were available for licensing and focused on getting those states up and running. Now that MariMed has consolidated the businesses in Illinois, Massachusetts and Maryland, we are focused on expanding to the maximum allowable by law in each of those states.

In Massachusetts, for example, we plan to add two more adult-use dispensaries to our fully vertical, seed-to-sale operation there. In Illinois, we recently added a cultivation-and-processing licence that, once operational, will make us fully vertical in that high-growth state, and we also acquired a licence to build a fifth adult-use dispensary. Illinois allows operators to own and operate a maximum of 10 dispensaries, so we are also focused on adding an additional five to maximize our retail operations in that state.

Additionally, we’re looking for other markets we can expand into that have limited licences and are within the larger regions we presently operate in. We can go in and do the same build out where we go fully vertical as quickly as possible.

What are MariMed’s plans to enhance shareholder value?  

We have an exciting future ahead of us. As I mentioned, we’re building out Illinois, Massachusetts and Maryland with additional locations. We’ve also recently won licences in Ohio and Connecticut. 

We’re also going to continue to expand into additional states through either acquisitions or through the licensing process. Then we’ll build them to be as fully vertical as quickly as possible.

We’re also going to expand our branded products, including Betty’s Eddies, Kalm Fusion, Bubby’s Baked and Vibations: High + Energy, which have all been very successful in each of the states in which they are presently distributed. We’re going to make them bigger and stronger, as well as expand them into additional states over the next several years.

How do you intend to finance your growth plans?

We’re presently cash-flow positive and generating additional cash every month. So, we’ve been using cash flow from operations to expand at a slower rate. But with the current down market making equity issuance not the best option for shareholders, there are opportunities to borrow non-dilutive money at attractive rates given our financial strength and clean balance sheet.

What impact, if any, has the government’s inability to introduce federal cannabis legalization had on your business?

It’s a disappointment for MariMed because we would like to see some form of the SAFE Banking Act passed. That’s less important for our company, as our strong management team has learned how to operate within these tough confines of borrowing and banking abilities for over a decade. The SAFE Banking Act is really about helping smaller cannabis entrepreneurs that are more challenged in gaining fair and equitable access to capital.

We would love to see the SAFE Banking Act passed, and with the right amount of social equity reform included in it. But even with the continued delays at the federal level, MariMed can still operate efficiently and successfully. We’re going full steam ahead in building additional opportunities for our investors.

Finally, what do your shareholders have to look forward to in the next 12 months? 

Our investors should expect continued success and growth. Over the next 12 months, we will open additional retail and cultivation facilities, generating more revenue, and increasing the number of consumers that can access our great brands. We’ve been very successful over the last few years, and we’re going to continue that trend.

Our shareholders should expect MariMed to have a strong balance sheet with the ability to expand our cash flow and to borrow money at reasonable rates to accelerate the expansion of our business to get to the next level. We may be considered a small MSO, but we are going to become much bigger. 

In this market, we have a wonderful opportunity to continue to grow. I think our shareholders will benefit from patience and expect that we will continue to grow over the next several years.

This story was featured in Canadian Securities Exchange Magazine.

Learn more about MariMed at marimedinc.com. 

CSE Issuer Stories, Magazine

Nabati Foods Global: Reach into retail, food service and international markets fuels expectations for strong growth in 2022

Consumers are making a conscious choice to eat more plant-based foods, both from a personal health perspective and to lessen their impact on the environment. Recently listed Nabati Foods Global (CSE:MEAL) is well positioned to benefit from this trend by providing natural, plant-based, gluten- and soy-free foods for consumers who make healthy eating a priority.

Operating since 2014, the family-founded food technology company has four signature product lines: dairy free cheesecakes, cheese alternatives, plant-based meats and a plant-based liquid egg alternative.

“There are a lot of consumers, so-called flexitarians, that are plant-based-curious and want to dip their toes into the water for the first time,” Nabati Foods interim Chief Executive Officer Michael Aucoin tells Canadian Securities Exchange Magazine. “And for us, that means providing the best experience possible – designing our products with great flavour and providing great product delivery.”

Aucoin brings more than 25 years of consumer packaged goods experience to his role, including as former Vice President of Sales at Hershey Canada. Nabati is relying on Aucoin’s expertise to help the company achieve its next phase of growth.

That growth is being driven by rising consumer demand for plant-based foods. In the United States, the market is valued at US$7 billion and expanded by 27% in 2020, according to the Plant-Based Foods Association. Interestingly, growth topped 25% in all US census regions, underscoring that the shift to healthier food choices is very broad-based in nature.

Nabati has already established first-mover advantage in one part of the Canadian marketplace with its Nabati Plant Eggz, a plant-based egg alternative that is free of all major allergens. The product is gluten-free, soy-free, cholesterol-free, vegan, kosher and made without genetically modified organisms (GMOs) or refined sugar.

Unlike other plant-based food producers that focus solely on the retail consumer, Nabati can also tailor its packaging to meet food service industry needs, a market segment that Aucoin says the company is attracting strong interest from, particularly due to the innovative nature of its products.

“A great example of this is our team being able to develop a cheese product that really mimics pizza cheese in terms of milk quality, which isn’t always the case with plant-based cheese, so we’re pretty excited about that,” Aucoin says.

According to Aucoin, the key to growing the company’s revenue is building a distribution network, and to that end Nabati already has products featured in more than 700 locations across North America. Some of its more recognizable nationwide retailers in Canada include Sobeys, Metro, Safeway, Whole Foods and online at Costco.ca, as well as food service outlets such as Cobs Bread and Mucho Burrito.

“The company has established distribution in South Korea, with other countries about to come on board,” Aucoin adds. In October 2021, Nabati announced that it was partnering with Nanum Foods to distribute Nabati Plant Eggz and dairy-free cheesecakes to retail store in South Korea and Vietnam. The products will be sold in Asia under the brand ITABAN.

Also in October, the company said it was partnering with IMCD Japan, a leading specialty chemicals and food ingredients distributor, to distribute Nabati’s full product line in Japan. The partnership will focus on distribution via food service, industrial and grocery channels.

“It’s about taking those great products and putting them in front of more consumers, building out our marketing plans to be able to communicate the quality of those products, and finding ways to have people sample. I think that’s one of the big opportunities across plant-based products,” Aucoin explains.

Aucoin says that Nabati has an innovative R&D team to determine how the company can evolve its product portfolio beyond the current four categories and capitalize on the next big plant-based food idea.

Over the next year, the interim CEO says he wants to see Nabati deliver “dramatic” revenue growth to a point where gross margin dollars translate all the way to the bottom line. 

“If you look at what our team’s done the last six to nine months, they’ve set up the business from an operational standpoint where we have material availability now to ship significantly more, which is a very good setup,” Aucoin says.

He adds that from a capacity perspective, the Nabati team has also been mindful of securing adequate inventories of strategic ingredients, as there’s been concern within the industry about availability of these crucial inputs.

In the longer term, Aucoin wants the company to continue to understand where the consumer is going and to enhance its brand to become an unquestioned leader in the plant-based space.

“In five to 10 years, we’ll have a material footprint in other major markets around the world, continue to evaluate whitespace opportunities from an R&D perspective to broaden our product line, and build upon our past success,” Aucoin concludes. “We’re very bullish about our future.”

This story was featured in the Canadian Securities Exchange magazine.

Learn more about Nabati Foods Global at https://invest.nabatifoods.com/.

CSE Issuer Stories, Magazine

Revitalist Lifestyle and Wellness: On a mission to treat mental health and chronic pain on a global scale with integrated care

An estimated 265 million people worldwide suffer from depression, with the related cost to society – financial and otherwise – almost too great to comprehend. A Stifel GMP research report published in January 2021 indicates that psychedelic-assisted psychotherapy clinics have an addressable market opportunity in the US alone of US$10 billion to $11 billion.

Knoxville, Tennessee-based Revitalist Lifestyle and Wellness (CSE:CALM) operates five ketamine infusion clinics in the United States. The company is dedicated to empowering individuals to achieve improved quality of life through a combination of comprehensive care and future-focused treatments provided by medical professionals, mental health experts and chronic pain specialists.

In a recent interview with Canadian Securities Exchange Magazine, Revitalist Chief Executive Officer Kathryn Walker discussed the company’s growth plans and the advantages of its business model.

How does Revitalist distinguish itself from other publicly traded mental wellness companies? What makes your model better?

Revitalist is the first clinic model to effectively integrate medical and mental health providers working in a team manner with each client. It’s something the medical community has been wanting to do for 30 years, but no one’s really known how to do it. Therapists have started working in medical providers’ offices, but they still don’t work seamlessly on the topic at hand.

The opportunity that we have with psychedelic treatments is that medical providers are making sure the client is safe while the mental health providers are intervening actively during the session, focusing on unfolding the unhealthy conditioning the brain has acquired through many years of ineffective treatments and therapies. We are the first effective model that is being actively covered by insurance, allowing us to expand access to individuals across the country.

What specific roles do psychedelics play in the treatment methods?

At this time, Revitalist primarily provides ketamine infusions. With the psychedelic piece, we have therapists that are trained through the FDA MAPS program. We also have anesthesia providers that have administered every intravenous medication, making them experts in critical care medicine and giving our clients that extra layer of safety and care.

Our anesthesia providers are oftentimes referred to as “pharmacologic physiologists.” In a time where psychedelics are being actively formed in research labs, an excellent person to have on your team is a pharmacologic physiologist. As the pharmacology piece evolves with FDA approval of these exciting medications, the big pharmaceutical companies will want CRNAs (Certified Registered Nurse Anesthetists) as part of their team, and Revitalist will be able to meet that need.

The mental health system is only about 30% effective with its current treatment models. This includes many of the medications that are prescribed, including SSRIs, SNRIs, TCAs and MAOIs. Anesthesia is more than 99% accurate.

What would you say has been Revitalist’s most significant accomplishment thus far?

I think the most significant accomplishment we have right now is in the works, where we are bringing the inpatient experts to the outpatient world. The providers we have with our company are all top line. They know how the current system operates, and they are aware of what should be converted to this system, and what should not.

Revitalist is here to create an entire new model of healthcare that will bridge the old system of health to the new system of psychedelics.

In the hospital sector, when a patient comes to the hospital, we know we have a team on standby and we are going to work together to give that person the best care they deserve. As medicine and insurance companies have evolved, so has our inpatient healthcare system. Now is the time to recreate a healthier structure that is more cost effective in an outpatient environment.

I personally think the mental health and medical system is imploding. The system is off balance, and everyone in and around it can feel that imbalance. We keep seeing more of it every day. Revitalist and the providers who know that system are reshaping a new one, and we are so ready and excited to do so. We’re able to address this issue not only locally and nationally, but also globally as our medical licenses are able to cross lines in over 39 countries.

The healthcare sector needs to recognize that it is in a transition period. It’s like changing homes. They need to leave behind what isn’t necessary and only take what makes sense for the system going forward. Only providers that understand the “old” system and realize the positivity of the “new” will be able to lead the bridged transition. The providers at Revitalist will be that bridge.

What needs to be done to take Revitalist to the next level? Talk about your growth strategy.

We plan on opening 48 clinics in 2021 and 2022 with a goal of having 157 locations in 2025.

What sets us apart is a shared governance with our clinic model. Our recruitment is key, and it makes us stand alone in this space. We have our lead providers, we have corporate personnel that can also act as providers, and we have our own locum providers. This allows us to create and keep consistency amongst every facility we open.

We provide every clinic we open with access to our operations teams, human resources departments, training centres, and marketing team, allowing robust support to everyone involved with our company.  And that upholds a quality of care that is consistent across the board.

Continuity of care is something we want every person that goes into a Revitalist to know and understand. If you are in Maine or in California and you see a Revitalist, you will know what you can expect from us.

Are the clinics you’re acquiring already profitable? What are their sources of revenue?

We’re probably doing a 90-10 split – that is, we are building 90% of the clinics and then acquiring approximately 10%. The space is very fragmented when it comes to psychedelics, and with ketamine clinics a lot of them are part-time clinics that are not making revenue. These are clinics that others seem to be acquiring, but this is a decision we feel would not benefit our company or our investors. Our location specialists analyze data for facility placements to find the biggest bang for our buck. We place our clinics with strong university presence and veteran hospitals, allowing continuation of our base revenue lines.

What do your shareholders have to look forward to in the next 12 months?

We have so many strategic partnerships coming to fruition. One of the biggest services we offer that sets us apart from the others is the fact that we accept federal and commercial insurance. We are also positioned with Veterans Affairs (VA). We have contracts allowing veterans to be directly referred to us under the protocols specific to the individual VA locations.

I think we’ll see insurance companies learn to accept it more. And we do have our own internal insurance team of specialists which, again, sets us apart immensely. We will be able to provide access to this on a cost-saving basis. If you look at what we need to operate, it’s about 10% cost-wise as compared to our competitors. We have so many projects going on behind the scenes, it’s going to be exciting seeing it all unfold.

One of the many reasons we are cost effective is because of the prices we charge. Our average is $275 per infusion, and I know some of our competitors charge on average around $1,200. If you’re charging $1,200, that’s really going to limit a lot of individuals’ access to these services, especially when they’re not accepting insurance. Given that we can accept insurance and our cost is significantly lower, I think you’ll see the need for our services develop much more quickly. For our investors, we’re working on becoming the first comprehensive psychedelic centre in the world.

This story was featured in the Canadian Securities Exchange magazine.

Learn more about Revitalist Lifestyle and Wellness at https://revitalist.com/